CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy

Allers, Kristina; Schneider, Thomas

doi:10.1016/j.coviro.2015.06.007

Cited by 61 publications

(57 citation statements)

References 44 publications

(38 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent novel strategies include neutralizing HIVspecific monoclonal antibodies (Barouch et al 2013), ART intensification (DaFonseca et al 2015), and gene editing (Allers and Schneider 2015;Khalili et al 2015). Since each strategy has some limitations, it is most likely that a functional cure may require a combination of various approaches.…”

Section: Current Potential Hiv Cure Strategiesmentioning

confidence: 99%

Might dolutegravir be part of a functional cure for HIV?

2016

View full text Add to dashboard Cite

Antiretroviral therapy (ART) has greatly decreased HIV-related morbidity and mortality. However, HIV can establish viral reservoirs that evade both the immune system and ART. Dolutegravir (DTG) is a secondgeneration integrase strand transfer inhibitor (INSTI) related to the first-generation INSTIs raltegravir (RAL) and elvitegravir (EVG). DTG shows a higher genetic barrier to the development of HIV-1 resistance than RAL and EVG. More interestingly, clinical resistance mutations to DTG in treatment-naïve patients have not been observed to date. This review summarizes recent studies on strategies toward a cure for HIV, explores resistance profiles of DTG, and discusses how DTG might help in finding a functional cure for HIV.Key words: dolutegravir, drug resistance, HIV, cure. Résumé :Les traitements antirétroviraux (TAR) ont considérablement réduit la morbidité et la mortalité associées au VIH. Or, le VIH peut établir des réservoirs viraux pour se soustraire au système immunitaire et aux TAR. Le dolutégravir (DTG) est un inhibiteur du transfert de brin par l'intégrase (integrase strand transfer inhibitor, INSTI) de deuxième génération qui s'apparente au raltégravir (RAL) et à l'elvitégravir (EVG), des INSTI de première génération. Comparativement au RAL et à l'EVG, le DTG présente une plus grande barrière génétique au dével-oppement de la résistance chez le VIH. On remarque avec intérêt que des mutations menant à la résistance clinique au DTG chez des patients jamais traités auparavant n'ont pas encore été observées. La présente revue fait la synthèse des études récentes abordant des stratégies visant à éliminer le VIH, explore les profils de résistance au DTG et discute de la possibilité de mettre au point un remède contre le VIH à l'aide du DTG. [Traduit par la Rédaction]

show abstract

Section: Current Potential Hiv Cure Strategiesmentioning

confidence: 99%

Might dolutegravir be part of a functional cure for HIV?

2016

View full text Add to dashboard Cite

show abstract

“…Allogeneic stem cell transplantations are too risky. In addition, lack of availability of naturally CCR5-deficient donor cells for stem cell transplantation is another major problem (Allers and Schneider 2015). Recently, genome-editing technologies that recognize specific DNA sequences are used for curing HIV.…”

Section: Discussionmentioning

confidence: 99%

Proteins, peptides, polysaccharides, and nucleotides with inhibitory activity on human immunodeficiency virus and its enzymes

Cheung

Wong

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Human immunodeficiency virus (HIV), the causative agent of acquired immune deficiency syndrome, has claimed innumerable lives in the past. Many biomolecules which suppress HIV replication and also other biomolecules that inhibit enzymes essential to HIV replication have been reported. Proteins including a variety of milk proteins, ribosome-inactivating proteins, ribonucleases, antifungal proteins, and trypsin inhibitors; peptides comprising cathelicidins, defensins, synthetic peptides, and others; polysaccharides and polysaccharopeptides; nucleosides, nucleotides, and ribozymes, demonstrated anti-HIV activity. In many cases, the mechanism of anti-HIV action has been elucidated. Strategies have been devised to augment the anti-HIV potency of these compounds.

show abstract

“…The hope is that the understanding of virus–cell interactions will continue to shed light on new biology (e.g., noncanonical mechanisms of translation initiation) and will also open up novel strategies to decrease viral pathogenesis by interfering with essential virus–cell interactions (e.g., blocking CCR5 to treat HIV infection). 333 In this review, we broadly cover the current knowledge of host factors, pro- and antiviral, that impact flavivirus replication with an emphasis on RNA binding proteins. We also refer the reader to other reviews.…”

Section: Pro-viral Host Factorsmentioning

confidence: 99%

“…418,419 A broader definition could include the absence of a pro-viral factor such as a deletion in the CCR5 gene in some human populations leading to HIV resistance. 333 Innate immunity usually refers to immune mechanisms that more broadly target multiple pathogens (viruses) and, in many cases, are induced upon infection. We will discuss host factors that act in both of these types of immunity and will emphasize the role of RBPs.…”

Section: Antiviral Factorsmentioning

confidence: 99%

Biochemistry and Molecular Biology of Flaviviruses

et al. 2018

View full text Add to dashboard Cite

Flaviviruses, such as dengue, Japanese encephalitis, tick-borne encephalitis, West Nile, yellow fever, and Zika viruses, are critically important human pathogens that sicken a staggeringly high number of humans every year. Most of these pathogens are transmitted by mosquitos, and not surprisingly, as the earth warms and human populations grow and move, their geographic reach is increasing. Flaviviruses are simple RNA–protein machines that carry out protein synthesis, genome replication, and virion packaging in close association with cellular lipid membranes. In this review, we examine the molecular biology of flaviviruses touching on the structure and function of viral components and how these interact with host factors. The latter are functionally divided into pro-viral and antiviral factors, both of which, not surprisingly, include many RNA binding proteins. In the interface between the virus and the hosts we highlight the role of a noncoding RNA produced by flaviviruses to impair antiviral host immune responses. Throughout the review, we highlight areas of intense investigation, or a need for it, and potential targets and tools to consider in the important battle against pathogenic flaviviruses.

show abstract

CCR5Δ32 mutation and HIV infection: basis for curative HIV therapy

Cited by 61 publications

References 44 publications

Might dolutegravir be part of a functional cure for HIV?

Might dolutegravir be part of a functional cure for HIV?

Proteins, peptides, polysaccharides, and nucleotides with inhibitory activity on human immunodeficiency virus and its enzymes

Biochemistry and Molecular Biology of Flaviviruses

Contact Info

Product

Resources

About